Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Immunotherapies/steroids/vedolizumab

Colitis and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yu K, et al. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Annals of Gastroenterology 35: No. 5, Sep-Oct 2022. Available from: URL: http://doi.org/10.20524/aog.2022.0742 Yu K, et al. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Annals of Gastroenterology 35: No. 5, Sep-Oct 2022. Available from: URL: http://​doi.​org/​10.​20524/​aog.​2022.​0742
Metadaten
Titel
Immunotherapies/steroids/vedolizumab
Colitis and lack of efficacy: case report
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25470-5

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Mepivacaine

Case report

Multiple drugs